Antimicrobial use and resistance in Democratic Republic of Congo: Implications and recommendations; A mini review
Aymar Akilimali(Roslin Institute), Bonk Muhoza(Université Officielle de Bukavu), Pierre Luundo(Université Officielle de Bukavu), Adolphe Aganze(Université Officielle de Bukavu), Rahma Sayadi(University of Monastir), Daniel Kachunga(Université Officielle de Bukavu), Alain Balume(Université Officielle de Bukavu), Malik Olatunde Oduoye(Ahmadu Bello University), Guillain Ramandizi(Université Officielle de Bukavu), Styves Banga(Université Officielle de Bukavu)
Cited by 8
Related Papers
Revolutionary breakthrough: FDA approves CASGEVY, the first CRISPR/Cas9 gene therapy for sickle cell disease
|Annals of Medicine and Surgery|2024|87
Impacts of the advancement in artificial intelligence on laboratory medicine in low‐ and middle‐income countries: Challenges and recommendations—A literature review
|Health Science Reports|2024|62
Revolutionary breakthrough: FDA approves Vyjuvek, the first topical gene therapy for dystrophic epidermolysis bullosa
|Annals of Medicine and Surgery|2023|30
Self-medication and Anti-malarial Drug Resistance in the Democratic Republic of the Congo (DRC): A silent threat
|Tropical Medicine and Health|2022|29